CNS drug discovery with translatable neuroscience technology
High attrition rates in CNS clinical trials is an indication that current testing is failing to predict safety/efficacy of compounds. NeuCyte supports early phases of drug discovery programs as well as the investigation of MOAs for experimental compounds. Based on the SynFire® technology, our human neural in vitro platforms are uniquely suited for assessing relevant higher order electrophysiology readouts, which allow for a better predictor of drug efficacy and potential CNS safety/toxicology.
Society of Toxicology
11190 Sunrise Valley Dr, Ste 300
Reston, VA 20191
Become An Exhibitor
Exhibitor Service Center
Virtual SOT Annual Meeting Website
Society of Toxicology. All rights reserved.
Copyright 2018, a2z, Inc. All rights reserved.